Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

(2019) Riyaz Shah et al.   Clinical Lung Cancer

Recent advances in the management of lung cancer

(2018) Gavin S Jones et al.   CLINICAL MEDICINE

Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors

(2018) Mahaveer Singh et al.   DRUG DISCOVERY TODAY

Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors

(2018) Yiqiang OuYang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing oxazole or imidazole as potential EGFR inhibitors

(2018) Yiqiang OuYang et al.   NEW JOURNAL OF CHEMISTRY

Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance

(2017) Harun Patel et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions

(2016) Jody C. Chuang et al.   EXPERT OPINION ON PHARMACOTHERAPY

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer

(2016) Zhendong Song et al.   JOURNAL OF MEDICINAL CHEMISTRY

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

(2016) K. Park et al.   Journal of Thoracic Oncology

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

(2016) Yong Jia et al.   NATURE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?

(2013) Xin Ye et al.   Journal of Thoracic Oncology

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

(2013) Hiromichi Yamane et al.   OncoTargets and Therapy

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

(2012) Tjeerd Barf et al.   JOURNAL OF MEDICINAL CHEMISTRY

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

(2010) Yan Xu et al.   CANCER BIOLOGY & THERAPY

Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification

(2010) Mohane Selvaraj Coumar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer

(2009) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)

(2008) Michele M. Corsini et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

(2008) Marc Ladanyi et al.   MODERN PATHOLOGY

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA